Zhe-Sheng Chen

Dr. Zhe-Sheng (Jason) Chen, M.D., PhD, is currently a Professor at College of Pharmacy and Health Sciences, St. John’s University. He joined St. John’s University in 2004 as an assistant professor. He established several research projects to study ABC transporters and multidrug resistance (MDR) as well as reversal of MDR in both in vitro and in vivo tumor models. During past years, his laboratory has been well funded by NIH and companies. He carried out his postdoctoral training at Fox Chase Cancer Center (Philadelphia, USA, 2000-2004) and Kagoshima University Faculty of Medicine (Japan, 1998-2000). He received his Ph.D. degree from Kagoshima University Faculty of Medicine (Japan, 1994-1998), Master degree from Sun Yat-Sen University School of Public Health (China, 1985-1988) and M.D. from Guangdong Medical and Pharmaceutical College (China, 1980-1985). Dr. Chen is an editor-in-chief of Journal of Cancer Research Updates, and New Developments on Chemistry, an editor of African Journal of Pharmacy and Pharmacology, Regional Editor of Recent Patents on Anticancer Drugs Discovery, a guest editor of Current Pharmaceutical Biotechnology, an editorial board member of more than 20 journals and a reviewer of more than 170 peer reviewed journals. He is also an Ad hoc reviewer of some grants such as NIH, NCI Special Emphasis Review Panel, OmniBus SEP-10, State Grant Reviewer for Louisiana, and grants for New Zealand, Poland, China, Hungary, and Netherlands etc. As a consultant to pharmaceutical, biotechnology and health industry organizations, Dr. Chen commands invitations for presentations, keynote addresses, and conference chairman. He published more than 150 publications in peer reviewed journals and 5 book chapters.

Teaching Interests

I am interested in teaching Pharmacology especially Cancer Pharmacology and Clinical Pharmacology, but I also enjoy teaching basic Pharmacology and Advance Pharmacology as well as Biochemistry etc.

Research Interests

Our primary goal is to develop more effective chemotherapeutic agents for cancer patients. Multidrug resistance (MDR) represents a major obstacle to the treatment of cancer, and understanding the resistance mechanisms and knowing how to reverse the

Courses Taught

BIT 352 SPECIAL RESEARCH IN BIOTECH

PHR 5108 DRUGS/NEOPLASTIC/ASSOC DISEASE

PHS 3509 INTRODUCTION TO PHARMACOLOGY